You searched for "Radiotherapy"
Demanding cases or nightmares in uro-oncology? Sep/Oct 2022
Treatment of prostate cancer in renal transplant recipients is challenging due to a lack of knowledge of the natural history of cancer in these patients, the anatomical position of the graft in the iliac fossa and its proximity to the...EAU (European Association of Urology) Masterclass on Focal therapy for localised prostate cancer
Focal Therapy (FT) is a promising treatment option aimed at improving the management of localised prostate cancer. This masterclass will provide you with an extensive review of the rationale for FT, the patient selection modalities and the available energy sources (HIFU, Cryo, IRE, Laser, Brachytherapy). Gain further knowledge and better understand the FT benefits.Onco-fertility: a review
Subfertility or infertility is a major problem affecting men diagnosed with testicular cancer (TC) either due to the disease itself [1], or as a result of management [2]. TC is the most prevalent cancer affecting men of reproductive age [3]....Focal therapy for prostate cancer – ready for prime time?
The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...
Phase two trial of SAbR for primary RCC
A study focused on stereotactic ablative radiotherapy (SAbR) as a treatment for primary renal cell carcinoma (RCC) has yielded significant findings. The primary objective of the study was successfully met, demonstrating a 94% local control rate at one year among...
Cryotherapy in prostate cancer
This review of the literature aims to summarise what is known in regards to outcomes in patients undergoing cryotherapy in a number of settings: whole gland, salvage and targeted focal therapy. It highlights that more prostate cancers are being diagnosed...Penile cancer: a practical approach
Penile cancer is rare and accounts for less than 1% of all new cancer cases in males in the UK, with around 640 new cases diagnosed every year [1]. In England and Wales, the annual incidence is between 1.2 and...Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...EMUC19 - 11th European Multidisciplinary Congress on Urological Cancers
Don’t miss the great opportunity to present your innovative research or to attend the 11th European Multidisciplinary Congress on Urological Cancers (EMUC19) from 14-17 November 2019 in Vienna, Austria. Registration is now open. You can submit your onco-urology abstract before...
Increased use of active surveillance for men with intermediate risk prostate cancer
The optimal management of men with intermediate risk prostate cancer remains unclear and continues to be debated. The authors interrogate the US National Cancer Database for 176,122 men diagnosed with intermediate risk prostate cancer between 2010 and 2016. Of these...
Urinary diversion and infections
This article will be of interest to colleagues undertaking reconstructive surgery. Urinary diversions have been performed for decades. Common indications are muscle-invasive bladder cancer, neurological disorders, inflammatory conditions and congenital malformation. The diversions could be continent or non-continent. Complications due...
